RCM
ALNY icon

Reynolds Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Reynolds Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,800
Closed -$264K – 114
2015
Q4 		$264K Buy
+2,800
New +$260K 0.29% 106

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Reynolds Capital Management's ALNY Position: Q1 2016 in Review

Reynolds Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2016, closing a stake of 2,800 shares — an estimated $264K sold.

Reynolds Capital Management first reported a position in ALNY in Q4 2015 and held it in 1 quarter. The position peaked at $264K in Q4 2015. 255 funds tracked by Wall St. Rank hold ALNY as of Q1 2016.

  • Reynolds Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Reynolds Capital Management sold 2,800 Alnylam Pharmaceuticals shares in Q1 2016, an estimated $264K.
  • Reynolds Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Reynolds Capital Management's Alnylam Pharmaceuticals position peaked at $264K in Q4 2015.
  • 255 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2016.

Based on Reynolds Capital Management's 13F filing for Q1 2016, filed 13 May 2016.